Long follow-up links baseline biomarkers
Baseline samples from untreated RRMS patients are connected to a median nine years of follow-up, including SPMS conversion and sustained PIRMA outcomes.
↳ Methods, Patients and Samples; Results, Fig. 4
Progressive multiple sclerosis is characterized by gradual neurological decline, often occurring independently of relapses or MRI activity-a phenomenon known as progression independent of relapse and MRI activity (PIRMA). Despite the effectiveness of disease-modifying therapies in controlling inflammatory activity, identifying individuals at risk of PIRMA remains an unmet clinical need. The objective of this exploratory study was to identify biomarkers and underlying molecular pathways associated with multiple sclerosis progression and especially PIRMA. Using the NUcleic acid Linked Immuno-Sandwich Assay (NULISA) inflammatory panel, we quantified 250 immune-related proteins in CSF and plasma from 49 controls, 49 patients with early active relapsing-remitting multiple sclerosis (RRMS) and 33 patients with inactive progressive multiple sclerosis (iPMS). Longitudinal clinical data were used to define PIRMA and conversion to secondary progressive multiple sclerosis (SPMS). We identified distinct proteomic signatures in CSF of both RRMS and iPMS patients compared with controls, with no significant differences in plasma. Both were associated with elevated markers of adaptive immunity, while iPMS showed a shift towards innate immune markers. Among RRMS patients, low baseline CSF concentrations of KIT ligand (KITLG) predicted both conversion to SPMS and future PIRMA events. Receiver operating characteristic analysis demonstrated KITLG's potential as a prognostic biomarker. Additionally, plasma concentrations of interleukin 1 beta and 36 gamma were elevated in RRMS patients who later developed SPMS. A model selection analysis identified a two-protein logistic regression model including interleukin 1 beta and interleukin 36 gamma as the best-performing combination (area under the curve = 0.990). Our findings reveal distinct immunological profiles across multiple sclerosis subtypes and identify KITLG as a promising biomarker for predicting disease progression and PIRMA. These results highlight potential targets for therapeutic intervention and demonstrate the utility of NULISA in uncovering novel molecular signatures in multiple sclerosis.
Among RRMS patients, low baseline CSF concentrations of KIT ligand (KITLG) predicted both conversion to SPMS and future PIRMA events.
small overlapping outcome groups, an internally derived cut-off, event-poor adjusted models, and no external validation
We identified distinct proteomic signatures in CSF of both RRMS and iPMS patients compared with controls, with no significant differences in plasma.
FDR-controlled adjusted CSF comparisons support the direction, while the small plasma sample limits confidence in the null result
A model selection analysis identified a two-protein logistic regression model including interleukin 1 beta and interleukin 36 gamma as the best-performing combination (area under the curve = 0.990).
the apparent AUC follows selection in a very small cohort without cross-validation and duplicates another model’s reported statistics
Derived from the full evaluation — not a separate score.
Strengths
Baseline samples from untreated RRMS patients are connected to a median nine years of follow-up, including SPMS conversion and sustained PIRMA outcomes.
↳ Methods, Patients and Samples; Results, Fig. 4
Samples followed the BioMS-EU handling protocol, and differential-expression analyses used age- and sex-adjusted models with FDR correction.
↳ Methods, NULISA Proteomic Analysis and Statistical Analysis
The Discussion compares the findings with prior CSF signatures and a large plasma proteomic study that reported broader alterations, rather than presenting the results in isolation.
↳ Discussion, first two paragraphs
Limitations
The IL1B–IL36G SPMS model and the CCL27–NGF–SPP1 PIRMA model report exactly the same AUC, confidence interval, and P-value, despite using different proteins and outcomes.
↳ Results, Fig. 5C and Fig. 5E
Proteins were filtered by outcome correlation and models were dredged by AICc, while validation was absent for plasma models and was not shown to encompass feature selection for the CSF models.
↳ Methods, Statistical Analysis; Results, Fig. 3 and Fig. 5
The prognostic analyses use few events, internally selected cut-offs, and no strong clinical-only comparator or external cohort. PIRMA and SPMS conversion also overlap substantially.
↳ Results, Fig. 4–5; Discussion, limitations
The study's strongest foundation is its treatment-naïve baseline cohort, standardized biofluid handling, and long follow-up for clinically relevant progression outcomes. Its cross-sectional CSF findings are supported by adjusted, FDR-controlled analyses, but much of that profile confirms existing biomarker literature. Confidence falls sharply for the prognostic models because proteins and cut-offs were selected internally, plasma models were not validated, and no clinical-only prognostic comparator was presented. The identical AUC, confidence interval, and P-value reported for two different plasma models, together with other Results–Discussion inconsistencies, requires correction before the headline performance claims can be relied upon.
Nabu’s assessment, alongside the field’s view.
Are you an author of this paper?
The study combines baseline CSF and plasma proteomics with long clinical follow-up and nominates KITLG as a potentially novel progression-associated marker. The advance remains incremental because much of the CSF profile is confirmatory and the prognostic findings have not been externally validated.
These results are largely confirmatory
Standardized sample handling, FDR-controlled expression analysis, covariate-adjusted Cox models, and internal cross-validation support the exploratory design. However, outcome-informed feature selection was not nested within validation, the plasma models were evaluated in the selection cohort, and no clinical prognostic baseline was tested.
the single best-performing model was selected
The article follows a coherent progression from cohort definition through proteomic comparison and prognostic analysis. Predictive language in the Abstract and Discussion overstates small internally selected models, while references to IKBKG, PTX3, and an unreported log-rank test interrupt the evidence chain.
KITLG as a promising biomarker for predicting disease progression and PIRMA
The Discussion engages prior CSF and plasma proteomic work, including a contrasting large plasma study, and acknowledges sample size and external-validation needs. It does not directly address selection-induced optimism in the reported AUCs or the substantial overlap between PIRMA and SPMS conversion.
external validation in independent cohorts is needed
Caveats4 of 4 checks
The Discussion introduces an unreported IKBKG result and a log-rank analysis not described in Methods or Results. Funding, conflict-of-interest and code-availability statements are absent from the supplied text; the conventional data-on-request statement is not itself a reliability concern.
Conflict of interest: not stated · Ethics approval: declared · Data availability: declared · Code availability: not stated
50 references in manuscript 50 of 50 checkable references found in an index
References not verified automatically are resolved manually within 24 hours.
No retraction or expression of concern found in Crossref (includes Retraction Watch).
Sources: Crossref (incl. Retraction Watch) ✓
The predictive performance of KITLG was demonstrated once in a single small exploratory cohort with internal cross-validation, and the authors state external validation in independent cohorts is still needed.
“plasma IL1B could serve as a potential biomarker for identifying RRMS patients at risk of transitioning to SPMS”
The paper names prognostic biomarker use and therapeutic targeting of IL1B/NLRP3, but does not specify which profession, organisation or clinical setting would act on the findings.
Neurologists could use validated CSF KITLG and plasma IL1B/IL36G tests to stratify RRMS patients at risk of progression and guide earlier treatment decisions.
The findings come from a modest single-centre exploratory cohort and require confirmation in independent cohorts and clinical settings before any prognostic test could be adopted.
Evaluated 13 Nov 2026 · GBD 2023 · glm_v1_3_3 · impact_profile_v1_3_3
AI-generated, human-governed. Something look off? Contact us to request a review.
Keep reading
Other papers Nabu has evaluated blind, starting with the same field.
Flintere-Flinte, Krutovs, Pantelejeva, et al. · 2026 · Clinical medicine
Serum NfL was found to be a reliable marker of disease activity and progression.
TentativeRosenstein, Axelsson, Johnsson, et al. · 2026 · Clinical medicine
Natalizumab appears to reduce intrathecal KFLC synthesis, and a decline in KFLC index may reflect effective suppression of CNS humoral immunity.
SupportedMorcom, Xia, Xu, et al. · 2026 · Basic medicine
These findings indicate that DNA damage burden and inadequate repair in CUX2+ L2/3ENs contributes to selective vulnerability in neuroinflammatory injury.
Supported